- Home
- NVAX vs ULCC Comparison
NVAX vs ULCC Comparison
Compare NVAX & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- ULCC
- Stock Information
- Founded
- NVAX 1987
- ULCC 1994
- Country
- NVAX United States
- ULCC United States
- Employees
- NVAX N/A
- ULCC N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ULCC Air Freight/Delivery Services
- Sector
- NVAX Health Care
- ULCC Consumer Discretionary
- Exchange
- NVAX Nasdaq
- ULCC Nasdaq
- Market Cap
- NVAX 1.4B
- ULCC 1.1B
- IPO Year
- NVAX 1995
- ULCC 2021
- Fundamental
- Price
- NVAX $7.19
- ULCC $4.04
- Analyst Decision
- NVAX Hold
- ULCC Hold
- Analyst Count
- NVAX 8
- ULCC 9
- Target Price
- NVAX $11.38
- ULCC $5.63
- AVG Volume (30 Days)
- NVAX 4.2M
- ULCC 3.7M
- Earning Date
- NVAX 11-06-2025
- ULCC 11-05-2025
- Dividend Yield
- NVAX N/A
- ULCC N/A
- EPS Growth
- NVAX N/A
- ULCC N/A
- EPS
- NVAX 2.07
- ULCC N/A
- Revenue
- NVAX $1,064,651,000.00
- ULCC $3,729,000,000.00
- Revenue This Year
- NVAX $59.49
- ULCC $1.14
- Revenue Next Year
- NVAX N/A
- ULCC $13.33
- P/E Ratio
- NVAX $3.47
- ULCC N/A
- Revenue Growth
- NVAX 20.27
- ULCC 1.77
- 52 Week Low
- NVAX $5.01
- ULCC $2.89
- 52 Week High
- NVAX $11.55
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- NVAX 36.23
- ULCC 48.73
- Support Level
- NVAX $7.08
- ULCC $3.70
- Resistance Level
- NVAX $7.90
- ULCC $4.14
- Average True Range (ATR)
- NVAX 0.37
- ULCC 0.26
- MACD
- NVAX -0.12
- ULCC 0.02
- Stochastic Oscillator
- NVAX 7.17
- ULCC 59.26
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.